Olanzapin: Perbedaan antara revisi

Jelajahi riwayat secara interaktif

Konten dihapus Konten ditambahkan

VisualTeks wiki

Revisi per 10 Februari 2024 11.44 sunting WanaraLima (bicara \| kontrib) 1.730 suntingan Dibuat dengan menerjemahkan halaman "User:Mr. Ibrahem/Olanzapine" Tag: Terjemahan Konten Terjemahan Konten v2		Revisi terkini sejak 16 Oktober 2024 15.03 sunting balikkan Hysocc (bicara \| kontrib) Pengguna terkonfirmasi, Peninjau 64.242 suntingan k Menghapus Kategori:Piperazina; Menambah Kategori:Senyawa 4-metil-1-piperazinil menggunakan HotCat
(6 revisi perantara oleh 4 pengguna tidak ditampilkan)
Baris 7: <!-- Legal status -->\|legal_AU=S4\|legal_CA=Rx-only\|legal_UK=POM\|legal_US=Rx-only <!-- Pharmacokinetic data -->\|bioavailability=60-65%<ref>{{cite journal\| last1 = Kassahun\| first1 = Kelem\| last2 = Mattiuz\| first2 = Edward\| last3 = Nyhart\| first3 = Eldon\| title = DISPOSITION AND BIOTRANSFORMATION OF THE ANTIPSYCHOTIC AGENT OLANZAPINE IN HUMANS\| issue = 1\| pages = 81–93\| journal = Drug Metabolism and Disposition\| volume = 25\| date = January 1, 1997\| url = http://dmd.aspetjournals.org/content/25/1/81.long\| doi = \| pmid = 9010634\| id = \| access-date = February 22, 2019\| archive-date = February 22, 2019\| archive-url = https://web.archive.org/web/20190222151933/http://dmd.aspetjournals.org/content/25/1/81.long\| url-status = live}}</ref><ref>{{cite journal \| vauthors= Callaghan JT, Bergstrom RF, Ptak LR, et al\| title = Olanzapine: pharmacokinetic and pharmacodynamic profile. \| journal = Clin Pharmacokinetics\| volume = 37 \| issue = 3 \| pages = 177–193 \| date = September 1999 \| pmid = 10511917\| doi = 10.2165/00003088-199937030-00001 }}</ref><ref>{{cite journal \| vauthors = Mauri MC, Volonteri LS, Colasanti A, et al\| s2cid = 43859718 \| title = Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. \| journal = Clinical Pharmacokinetics \| volume = 46 \| issue = 5 \| pages = 359–88 \| date = 2007 \| pmid = 17465637\| doi = 10.2165/00003088-200746050-00001 }}</ref>\|protein_bound=93%<ref name = TGA>{{cite web\|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS\|work=TGA eBusiness Services\|publisher=Sandoz Pty Ltd\|date=8 June 2012\|accessdate=26 November 2013\|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|format=PDF\|archive-date=17 October 2015\|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|url-status=live}}</ref>\|metabolism=Liver (direct glucuronidation and [[CYP1A2]] mediated oxidation)\|elimination_half-life=33 hours, 51.8 hours (elderly)<ref name = TGA~~>{{cite~~ ~~web\|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg~~/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS\|work=TGA eBusiness Services\|publisher=Sandoz Pty Ltd\|date=8 June 2012\|accessdate=26 November 2013\|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|format=PDF\|archive-date=17 October 2015\|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|url-status=live}}</ref>\|excretion=Urine (57%; 7% as unchanged drug), faeces (30%)<ref name = TGA~~>{{cite~~ ~~web\|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg~~/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS\|work=TGA eBusiness Services\|publisher=Sandoz Pty Ltd\|date=8 June 2012\|accessdate=26 November 2013\|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|format=PDF\|archive-date=17 October 2015\|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3\|url-status=live}}</ref><ref name = MSR>{{cite web\|title=Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more\|accessdate=26 November 2013\|work=Medscape Reference\|publisher=WebMD\|url=http://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979#showall\|archive-date=2 December 2013\|archive-url=https://web.archive.org/web/20131202221232/http://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979#showall\|url-status=live}}</ref> <!--Chemical data-->\|C=17\|H=20\|N=4\|S=1\|molecular_weight=312.439\|smiles=CN1CCN(CC1)C/2=N/c4ccccc4Nc3sc(C)cc\23\|StdInChI_Ref={{stdinchicite\|correct\|chemspider}}\|StdInChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3\|StdInChIKey_Ref={{stdinchicite\|correct\|chemspider}}\|StdInChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N\|melting_point=195\|solubility=Practically insoluble in water}} '''~~Olanzapine~~Olanzapin''' adalah golongan antipsikotik atipikal yang digunakan untuk mengatasi [[skizofrenia]] dan [[gangguan bipolar]] . <ref name="AHFS2018">{{Cite web\|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live \|access-date=24 December 2018}}</ref> Pada pasien skizofrenia, obat ini bisa digunakan untuk jangka pendek dan bisa digunakan terapi pemeliharaan jangka panjang. <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> Rute pemberian obat melalui oral atau bisa [[penyuntikan intraotot]] . <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> Kemunculan efek samping yang umum pada penggunaan obat ini meliputi penambahan berat badan, gangguan pergerakan, pusing, rasa lelah, sembelit, dan mulut kering. <ref name="AHFS2018"~~>{{Cite~~ ~~web\|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live \|access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html "Olanzapine, Olanzapine Pamoate Monograph for Professionals"]. ''Drugs.com''. AHFS. [https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html Archived] from the original on 6 November 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> Efek samping lainnya yang bisa terjadi pada penggunaan obat ini yakni [[Hipotensi ortostatik\|hiptensi ostostatik]], [[Alergi\|reaksi alergi]], sindrom neuroleptik maligna, [[hiperglikemia]], [[sawan]], [[ginekomastia]], [[disfungsi ereksi]], dan tardive dyskinesia . <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> Penggunaan obat ini golongan lansia dengan riwayat [[demensia]], meningkatkan risiko kematian. <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> Untuk penggunaan trismester akhir pada [[kehamilan]] bisa menyebabkan gangguan pergerakan pada bayi selama beberapa waktu pasca dilahirkan. <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> Walaupun mekanisme kerjan dari obat ini belum sepenuhnya jelas, obat ini bisa memblokir [[Reseptor serotonin\|reseptor]] dopamin dan serotonin. <ref name="AHFS2018"~~>{{cite~~ ~~web \|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|website=Drugs.com \|publisher=AHFS \|accessdate=24 December 2018 \|language=en \|archive-date=6 November 2018 \|archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html \|url-status=live }}</ref> == Referensi == [[Kategori:~~Obat~~Perangsang nafsu makan]] [[Kategori:~~Farmasi~~Obat yang dikembangkan oleh Eli Lilly and Company]] [[Kategori:~~Psikiatri~~Amidina]] [[Kategori:Antagonis 5-HT2A]] [[Kategori:Antagonis 5-HT2B]] [[Kategori:Antagonis 5-HT2C]] [[Kategori:Antagonis 5-HT6]] [[Kategori:Antagonis 5-HT7]] [[Kategori:Penghalang alfa-1]] [[Kategori:Penghalang alfa-2]] [[Kategori:Antipsikotik atipikal]] [[Kategori:Antagonis D1]] [[Kategori:Antagonis D2]] [[Kategori:Antagonis D3]] [[Kategori:Antagonis D4]] [[Kategori:Antagonis D5]] [[Kategori:Antagonis reseptor H1]] [[Kategori:Antagonis reseptor H2]] [[Kategori:Antagonis muskarinik]] [[Kategori:Senyawa 4-metil-1-piperazinil]] [[Kategori:Tienobenzodiazepina]] [[Kategori:Obat Esensial Organisasi Kesehatan Dunia]] <references />{{Farmasi-stub}}